10-Q: Ekso Bionics Reports Q3 2024 Results, Revenue Declines Amidst Cost-Cutting Efforts

Ekso Bionics' Q3 2024 results show a decrease in revenue compared to the same period last year, alongside reduced operating expenses and a net loss.

Summary

• Ekso Bionics reported a net loss of $2.1 million for the third quarter of 2024, compared to a net loss of $3.4 million in the same period of 2023.
• Revenue for the quarter decreased by 10% to $4.1 million, primarily due to lower sales in both the EksoHealth and EksoWorks segments.
• Operating expenses decreased by 10% to $4.8 million, driven by reductions in sales and marketing and research and development costs.
• The company's gross profit margin remained relatively stable at 53%.
• For the nine months ended September 30, 2024, the net loss was $7.9 million, compared to $12 million in the same period of 2023.
• The company's cash and restricted cash balance was $8.3 million as of September 30, 2024, with $2 million restricted due to a loan agreement.
• The company raised approximately $5 million in net proceeds from a public offering in September 2024 and $3.9 million in January 2024.
• The company has a liquidity covenant requiring minimum cash on hand equivalent to the outstanding principal balance of their term loan.

Sentiment

Score: 4

Explanation: The document shows a mixed picture. While the company has improved its net loss and reduced operating expenses, the revenue decline and the going concern warning are significant concerns. The need for further capital raises also adds to the uncertainty.

Positives

• The company's net loss improved significantly in both the third quarter and the nine-month period compared to the previous year.
• Operating expenses were reduced, indicating successful cost-cutting measures.
• The company successfully raised capital through public offerings, strengthening its financial position.
• Gross profit margin remained stable at 53% despite a decrease in revenue.
• The company has a non-cancellable backlog of $3.4 million related to customer orders.

Negatives

• Revenue decreased by 10% in Q3 2024 compared to Q3 2023, indicating a decline in sales.
• The company continues to operate at a loss, despite improvements in net loss.
• The company has a liquidity covenant requiring minimum cash on hand equivalent to the outstanding principal balance of their term loan.
• The company has an accumulated deficit of $247 million.

Risks

• The company's ability to continue as a going concern is in doubt due to ongoing operating losses and the need for additional funding.
• The company's revenue is highly dependent on market demand for its exoskeleton products, which is influenced by various factors including economic conditions and reimbursement levels.
• The company faces competition in the medical device and industrial robotics markets.
• The company's business plan depends on sales of its Ekso Indego Therapy product to individuals with SCI who are covered by Medicare or Medicaid, and any changes to reimbursement policies could impact sales.
• The company must obtain certain regulatory approvals in the EU, which could be costly and time-consuming.
• The company may be diluted from future issuances of equity securities.
• The company may not achieve profitability in the near term or at all.

Future Outlook

Management intends to raise funds through one or more financings to support planned operations. The company plans to grow and expand its EksoHealth segment, increase revenue following the establishment of Medicare CMS reimbursement of the Ekso Indego Personal device, and pursue strategic initiatives.

Management Comments

• Management intends to raise funds through one or more financings.
• Management plans include delaying or abandoning certain product development projects, cost reduction efforts for our products, and refocused sales efforts to accelerate revenue growth above historical results if sufficient additional financings are not completed.

Industry Context

The company operates in the medical device and industrial robotics markets, which are highly competitive and subject to technological advancements. The company's performance is influenced by factors such as market demand, reimbursement policies, and economic conditions. The recent approval of CMS reimbursement for the Ekso Indego Personal device is expected to drive demand for this product.

Comparison to Industry Standards

• The company's revenue decline of 10% in Q3 2024 is concerning, as many medical device companies are experiencing growth in the current market.
• The company's gross margin of 53% is within the typical range for medical device companies, but there is room for improvement.
• The company's operating expense reduction of 10% is a positive sign, but further cost-cutting measures may be needed to achieve profitability.
• The company's reliance on external financing is a risk, as many successful medical device companies are able to generate positive cash flow from operations.
• The company's ability to obtain CE certificates for its products is critical for its expansion into the European market, and delays in this process could hinder growth.

Related Party Transactions

• The company entered into a mutual release and settlement agreement with an entity to settle and resolve any and all potential claims brought forth in connection with a consulting agreement executed between the entity and the Company in July 2017. A member of the Company's board of directors is affiliated with one of two entities under common control.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity issuances.
• Employees may be affected by potential cost-cutting measures and changes in product development plans.
• Customers may experience changes in product availability and service offerings.
• Creditors face the risk of non-payment if the company is unable to secure additional financing.

Next Steps

• The company intends to raise funds through one or more financings.
• The company plans to grow and expand its EksoHealth segment.
• The company will work to increase revenue following the establishment of Medicare CMS reimbursement of the Ekso Indego Personal device.
• The company will pursue strategic initiatives.

Key Dates

Keywords

exoskeleton, medical devices, rehabilitation, EksoHealth, EksoWorks, revenue, net loss, operating expenses, capital raise, warrants, Medicare, CMS, financial results